AlphAIAlphAI — Financial news for AI agents
NasdaqJAN 243 min read$RLMD

Leerink Partners Upgrades Relmada Therapeutics (RLMD)

Leerink Partners has upgraded Relmada Therapeutics (RLMD) from Market Perform to Outperform, with an average one-year price target of $10.20 per share, suggesting a 160.54% upside. Institutional ownership in RLMD increased by 49.27% in the last quarter, and the put/call ratio indicates a bullish outlook for the company.

Original reporting
Nasdaq · George Maybach for Fintel
Published Jan 24, 2026, 9:57 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jan 24, 2026, 10:00 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Leerink Partners Upgrades Relmada Therapeutics (RLMD) — source image
Source · Nasdaq
Decision brief

The 30-second read

$RLMDBullishHigh
01

Why it matters

The upgrade and institutional activity could lead to increased trading volume and liquidity, attracting more investors and potentially driving the stock price higher.

02

Market read

This news is highly relevant for investors interested in biotech and life sciences sectors, especially those focusing on innovative therapeutics with high growth potential.

03

What to watch

Potential market overreaction; need to monitor upcoming clinical trial results and regulatory decisions that could impact stock performance.

Timing: Immediate to short-term (next 1-3 months)

Background

Relmada Therapeutics is a biotech company focused on developing novel treatments for pain management. The recent upgrade by Leerink Partners reflects increased confidence in its pipeline and growth prospects.

Company-level read

Ticker impact

$RLMDBullishHigh confidence
Context

High relevance due to recent upgrade and institutional activity.

Expected impact

Potential significant upward movement, possibly exceeding 20% in the near term, contingent on market conditions.

Evidence & confidence

The upgrade from Market Perform to Outperform, a substantial increase in institutional ownership (49.27%), and a bullish put/call ratio collectively indicate strong positive momentum. The analyst's one-year price target of $10.20 implies a 160.54% upside from current levels, supporting a bullish outlook.

Market effects

Sector

Positive impact on the life sciences sector, especially biotech and pharmaceutical stocks with similar profiles.

Regional

Limited regional impact; primarily relevant to US markets where RLMD is listed.

Global

Moderate; reflects sector-specific developments rather than broad global market shifts.

Counterpoint

What could challenge this read

The biotech sector can be volatile; the upgrade may already be priced in, and any delays in drug development or regulatory setbacks could negate gains.

Key entities

  • Company
    Relmada Therapeutics

    A biotech firm specializing in pain management therapeutics.

  • Financial Institution
    Leerink Partners

    An investment bank and financial services firm that upgraded RLMD.

Read at source← All news

Related articles

AUG 14
$RLMDMed

Relmada (RLMD) Q2 2026 Earnings Call Transcript

Relmada Therapeutics (RLMD) reported Q2 2026 results and an execution update. Cash was $217.7M at June 30, 2026, funding operations through 2029. Net loss was $12.9M ($0.11/share). Management expects IND filings for NDV-01 and sepranolone by end-2026 and Phase 3 RESCUE enrollment to start after IND clearance.

fool.com6 min
AUG 6
$RLMDMed

RELMADA THERAPEUTICS, INC. (RLMD): Results of Operations and Financial Condition

RELMADA THERAPEUTICS, INC. (RLMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Relmada Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update ● Advancing NDV-01 toward IND filing expected by year-end 2026 with GMP manufacturing of clinical trial material underway. Initiation of the Phase 3 RESCUE registrational

SEC EDGAR 8-K6 min
SEP 14
$PYPLMed

PayPal’s New CEO Bets on Going It Alone After $50B Buyout

PayPal CEO Dan Schulman aims to revamp the company's struggling businesses, launch new features, and cut costs. His plan includes transforming Venmo into a full money-management tool and improving the checkout button. Rival offers for PayPal, including one from Stripe and Advent International, fell through, and shares have since declined. Schulman's turnaround strategy also involves expanding Venmo's crypto trading and PYUSD stablecoin. According to the Wall Street Journal, some analysts remain

pymnts.com3 min
SEP 14
$CMGMed

2 Monster Stocks to Buy and Hold for at Least the Next 5 Years

Chipotle (CMG) expanded internationally via partnerships, opening in South Korea and Mexico. It plans further Asian expansion. Domestically, it relaunched rewards to combat softer sales. e.l.f. Beauty (ELF) launches rhode in Europe, targeting a large existing social media following. Both companies aim for long-term growth through international markets.

fool.com3 min
SEP 13
$PEPMed

Publicis wins PepsiCo global media business

Publicis Groupe won PepsiCo’s global media business, consolidating strategy and technology under a new 'One PepsiCo' structure. PepsiCo spent $5.4B on marketing in 2025, including $3.4B on advertising. Publicis may withdraw from Coca-Cola’s media review. PepsiCo aims to modernize media operations with AI and data.

reel360.com2 min
SEP 13
$LHXHighAI 9/10

L3Harris, with Northampton plant, lands historic $4.7B Patriot missile contract

L3Harris Technologies secured a $4.7 billion, seven-year contract with Lockheed Martin for PAC-3 missile propulsion systems. The deal supports large-scale production of interceptors for tactical and cruise missiles. L3Harris, valued at $60B-$65B, did not disclose if work will occur at its Northampton plant. The contract aligns with a broader $58.6B DoD agreement to increase PAC-3 production.

gazettenet.com2 min